Global gene therapy doesn’t struggle only with science. It struggles with where and how therapies are made. Cross-border manufacturing is slow. Regulations don’t align. Supply chains break under pressure.
That’s the gap Andelyn Biosciences and ENCell Co., Ltd. are targeting with their new collaboration.
The partnership introduces a direct manufacturing bridge between the United States and Asia-Pacific (APAC). Instead of treating regions as separate execution zones, the companies are building a connected workflow.
What that enables:
The ambition is simple: Make global development feel local.
Gene therapy is not like traditional pharma manufacturing.
It depends on:
That makes scaling across regions difficult. A fragmented system leads to:
This partnership directly addresses those pain points.
This is not just a capacity-sharing deal. It changes execution.
1. In-Country Manufacturing for Trials
Sponsors can produce therapies where trials are conducted.
This aligns better with regional regulatory expectations.
2. Faster Tech Transfer Between Regions
Instead of rebuilding processes, companies can transition seamlessly between facilities.
3. Simplified Global Expansion
A coordinated system reduces duplication and operational complexity.
4. Shorter Time to Market
Less friction means faster movement from development to commercialization.
Andelyn Biosciences
ENCell Co., Ltd.
Together, they offer something rare: true cross-continental manufacturing execution
CEO Wade Macedone positioned the partnership as a step toward a seamless global manufacturing network.
That signals long-term intent: This is about building infrastructure, not just supporting individual projects.
Similarly, Jong Wook Chang highlighted the goal of expanding the global CGT ecosystem, connecting development, trials, and commercialization.
This collaboration reflects a broader transition in pharma: Centralized manufacturing is giving way to distributed global networks.
Why this shift is happening:
The dual-hemisphere model fits directly into this new reality.
Key signals to track:
If execution matches ambition, this model could become a blueprint for future CDMO collaborations.
This partnership is not just about capacity. It’s about removing structural friction in global gene therapy development. If successful, it could deliver:
In gene therapy, manufacturing is often the constraint. And this is a direct attempt to remove it.